| Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection C Phetsouphanh, DR Darley, DB Wilson, A Howe, C Munier, SK Patel, ... Nature immunology 23 (2), 210-216, 2022 | 666 | 2022 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 438 | 2021 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 327 | 2021 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 127 | 2022 |
| SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants F Tea, A Ospina Stella, A Aggarwal, D Ross Darley, D Pilli, D Vitale, ... PLoS medicine 18 (7), e1003656, 2021 | 120 | 2021 |
| SARS-CoV-2 Omicron BA. 5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern A Aggarwal, A Akerman, V Milogiannakis, MR Silva, G Walker, AO Stella, ... EBioMedicine 84, 2022 | 80 | 2022 |
| SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern A Aggarwal, AO Stella, G Walker, A Akerman, V Milogiannakis, F Brilot, ... medrxiv, 2021.12. 14.21267772, 2021 | 63 | 2021 |
| Persistent symptoms up to four months after community and hospital‐managed SARS‐CoV‐2 infection DR Darley, GJ Dore, L Cysique, KA Wilhelm, D Andresen, K Tonga, ... The Medical Journal of Australia 214 (6), 279, 2021 | 54 | 2021 |
| Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia A Aggarwal, AO Stella, G Walker, A Akerman, C Esneau, V Milogiannakis, ... Nature Microbiology 7 (6), 896-908, 2022 | 33 | 2022 |
| Emergence and antibody evasion of BQ, BA. 2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level A Akerman, V Milogiannakis, T Jean, C Esneau, MR Silva, T Ison, ... EBioMedicine 90, 2023 | 23 | 2023 |
| Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study LA Cysique, D Jakabek, SG Bracken, Y Allen-Davidian, B Heng, S Chow, ... Medrxiv, 2022.06. 07.22276020, 2022 | 22 | 2022 |
| Limited recovery from post-acute sequelae of SARS-CoV-2 at 8 months in a prospective cohort DR Darley, GJ Dore, AL Byrne, ML Plit, BJ Brew, A Kelleher, GV Matthews ERJ Open Research 7 (4), 2021 | 21 | 2021 |
| Practices of therapeutic drug monitoring in tuberculosis: an international survey I Margineanu, O Akkerman, D Cattaneo, D Goletti, DJE Marriott, ... European Respiratory Journal 59 (4), 2022 | 19 | 2022 |
| Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review HE Braithwaite, DR Darley, J Brett, RO Day, JE Carland Transplantation Reviews 35 (2), 100610, 2021 | 18 | 2021 |
| Eosinophils in transbronchial biopsies: a predictor of chronic lung allograft dysfunction and reduced survival after lung transplantation—a retrospective single‐center cohort … DR Darley, J Ma, E Huszti, P Fiset, L Levy, DM Hwang, P Pal, W Klement, ... Transplant International 34 (1), 62-75, 2021 | 18 | 2021 |
| Surveillance bronchoscopy: is it still relevant? M Benzimra Seminars in Respiratory and Critical Care Medicine 39 (02), 219-226, 2018 | 14 | 2018 |
| The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC LA Cysique, D Jakabek, SG Bracken, Y Allen‐Davidian, B Heng, S Chow, ... Annals of Clinical and Translational Neurology 10 (8), 1338-1352, 2023 | 13 | 2023 |
| COPD treatment choices based on blood eosinophils: are we there yet? B Oliver, K Tonga, D Darley, S Rutting, X Zhang, H Chen, G Wang Breathe 15 (4), 318-323, 2019 | 13 | 2019 |
| Donor‐derived tuberculosis (TB): isoniazid‐resistant TB transmitted from a lung transplant donor with inadequately treated latent infection TO Jensen, DR Darley, EE Goeman, K Shaw, DJ Marriott, AR Glanville Transplant Infectious Disease 18 (5), 782-784, 2016 | 13 | 2016 |
| Approaches to the management of sensitized lung transplant candidates: findings from an international survey M Aversa, DR Darley, A Hirji, L Snyder, D Lyu, F Parquin, M Perch, ... The Journal of Heart and Lung Transplantation 39 (4), S315, 2020 | 11 | 2020 |
Gail MatthewsKirby Institute, University of New South WalesVerified email at kirby.unsw.edu.au
